VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

S. equi Subunit EAG, FNZ and SFS Protein Vaccine
Vaccine Information
  • Vaccine Name: S. equi Subunit EAG, FNZ and SFS Protein Vaccine
  • Target Pathogen: Streptococcus equi
  • Target Disease: Strangles (also equine distemper)
  • Vaccine Ontology ID: VO_0011544
  • Type: Subunit vaccine
  • Status: Research
  • binding protein Eag gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Fnz gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Sfs gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0001272
    • Description: The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin (Flock et al., 2004).
  • Immunization Route: Subcutaneously
Host Response

Mouse Response

  • Vaccination Protocol: Mice were immunized either subcutaneously (s.c.) or intranasally (i.n.). For each antigen (FNZ, SFS, and EAG), 12 μg of antigen was mixed with an equal amount of EtxB so that all components achieved a final concentration of 300 μg/ml. In the case of i.n. immunization, the total volume was kept to less than 40 μl and applied into the nostrils of anaesthetized mice . For both s.c. and i.n. immunizations, four doses were given with 1-week intervals (Flock et al., 2004).
  • Challenge Protocol: Challenge i.n. with S. equi subsp. equi (10^6 CFU in a 10-μl volume) was given 1 week after the last booster dose (Flock et al., 2004).
  • Efficacy: It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) (Flock et al., 2004).
  • Host IgA response
    • Description: An analysis of the bronchoalveolar lavage (BAL) fluid taken after the last immunization revealed significant IgA levels to EAG in the animals immunized with the three antigens and the EtxB adjuvant. By contrast, mice immunized with the three S. equi antigens in the absence of EtxB gave significantly lower IgA responses (Flock et al., 2004).
    • Detailed Gene Information: Click Here.
References
Flock et al., 2004: Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A, Guss B, Flock JI. Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses. Infection and immunity. 2004; 72(6); 3228-3236. [PubMed: 15155624].